NEW YORK, Sept. 5, 2017 /PRNewswire/ -- Hoth
Therapeutics Inc., a Nevada
corporation ("Hoth" or the "Company"), a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema, announced today the addition of Dr.
Andrew Herr, PhD, to the Company's
Technology Advisory Board. The Technology Advisory Board was
formed to assist the Company in developing the BioLexa
Platform. The BioLexa Platform is a proprietary, patented,
drug compound platform developed at the University of Cincinnati.
Robb Knie, CEO of Hoth stated,
"We are leveraging the investment made by Spherix Incorporated
(NASDAQ: SPEX) to expand and grow the BioLexa Platform by adding
Dr. Herr to our Technology Advisory Board. Dr. Herr is a
leader in his field, with a distinguished career. Dr. Herr
was instrumental in the creation and development of the BioLexa
Platform, so we are honored to have him on our advisory board and
grateful for his assistance to the Company. According to the
National Eczema Association, this chronic skin condition affects
approximately 32 million Americans and is a multibillion dollar
market in the U.S. alone. We are excited to be working
towards improving the lives of those affected."
Dr. Andrew Herr, PhD, is an
associate professor in the Division of Immunobiology and Center for
Systems Immunology, with an affiliate appointment in the Division
of Infectious Diseases at Cincinnati Children's Hospital within the
UC Department of Pediatrics. Dr. Herr completed his thesis work in
molecular biophysics from Washington
University in St. Louis,
and completed his postdoctoral work in structural immunology at the
California Institute of Technology as a
Damon Runyon Research Fellow. He was recruited to the University of Cincinnati College of Medicine as an
Ohio Eminent Scholar in Structural Biology before moving to
Cincinnati Children's Hospital.
The Herr lab studies mechanisms of bacterial pathogenesis.
Specifically, they discovered the zinc-dependent mechanism of
intercellular adhesion in bacterial biofilms formed by
Staphylococcus epidermidis and S. aureus. Biofilms
are specialized bacterial colonies that are highly resistant to
antibiotics and immune responses, so developing novel therapies to
prevent biofilm formation is of high importance. This is of
particular significance in eczema, since nearly 90% of people who
suffer from atopic dermatitis are colonized by S. aureus on
their skin. Dr. Herr also solved the first structure of a human
IgA1 antibody bound to its cognate Fc receptor while at Caltech,
and his lab has continued to study antibodies and immune receptors
implicated in autoimmune diseases. In addition, the lab is studying
a family of related collagen-specific immune receptors such as
glycoprotein VI, which activates platelets upon exposure to fibrous
collagen.
Before joining the faculty at Cincinnati Children's within the
University of Cincinnati College of
Medicine, Dr. Herr was an Ohio Eminent Scholar in Structural
Biology at the University of Cincinnati
College of Medicine and served as an associate director of the
Cincinnati Medical Scientist (MD/PhD) Training Program. Dr. Herr
received the 2014 Emerging Entrepreneurial Achievement Faculty
Award from UC for his work to commercialize a novel anti-infective
therapy based on his lab's research.
About Hoth Therapeutics Incorporated
Hoth Therapeutics Inc., a Nevada corporation, is a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. We are a small
company with limited financial resources and our scientific
background and abilities to implement a commercialization strategy
is subject to ever-changing market conditions and rapidly-advancing
technologies over which we have no control. While we believe that
these forward-looking statements are reasonable, market conditions
and competition in the marketplace is ever-changing and we have no
control over these influences. As a result, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC")
including, but not limited to, the Risk Factors relating to the
Company's patent business and other aspects of the Company's
business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
View original
content:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-the-addition-of-dr-andrew-herr-to-the-companys-technology-advisory-board-300513382.html
SOURCE Hoth Therapeutics Inc.